Soluble Alkaline Phosphatase Enzyme Replacement for Pediatric Hypophosphatasia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hypophosphatasia (HPP) are ineffective in addressing physical impairments and pain associated with the disease, particularly in children, leading to significant limitations in daily activities and motor development.
Innovation Solution
Administration of a soluble alkaline phosphatase (sALP), such as asfotase alfa, at a dosage of 6 mg/kg/week to children aged 5-12 years, using standardized tests like the Bruininks-Oseretsky Test of Motor Proficiency 2nd Edition (BOT-2), Childhood Health Assessment Questionnaire (CHAQ), and Pediatric Outcomes Data Collection Instrument (PODCI) to assess and improve physical function and pain management.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for HPP, then the disease progression is slow, but physical impairments and motor development remain severely limited
Solution Approach 1:
The patent changes the biochemical parameter by administering soluble alkaline phosphatase (sALP) to replace the defective enzyme, thereby altering the metabolic pathway and improving bone mineralization. This enzymic replacement changes the biochemical environment to correct the underlying defect in HPP, simultaneously addressing disease progression and physical function.
Solution Approach 2:
The sALP acts as an intermediary substance that mediates between the defective metabolic pathway and the desired physiological outcome. By introducing this external enzyme, the patent creates a bridge that enables proper bone mineralization and improves motor development without requiring direct genetic correction.
2Duration of action of moving object
If treatment duration is extended to improve long-term outcomes, then motor proficiency improves, but treatment complexity and monitoring requirements increase
Solution Approach 1:
The patent implements a feedback mechanism by using standardized assessments (BOT-2, CHAQ, PODCI) to monitor treatment response over time. This systematic feedback allows clinicians to adjust treatment duration and dosage based on objective measurements of motor proficiency improvement, thereby managing treatment complexity through structured evaluation.
Solution Approach 2:
The patent establishes baseline measurements before initiating treatment, allowing for preliminary assessment of motor function. This preliminary action creates a reference point that simplifies ongoing monitoring by enabling direct comparison of progress against established baselines, reducing the complexity of long-term evaluation.
3Productivity
If sALP dosage is increased to improve motor proficiency scores, then physical abilities improve, but risk of adverse effects increases
Solution Approach 1:
The patent employs dynamic dosage adjustment, starting with lower doses and gradually increasing to 6 mg/kg/week based on individual response and tolerance. This dynamic approach allows the treatment to adapt to the patient's changing needs and tolerance levels, maximizing motor proficiency improvement while minimizing adverse effects through gradual acclimatization.
Solution Approach 2:
The patent uses a moderate dosage of 6 mg/kg/week that provides sufficient enzymic replacement to achieve therapeutic benefits without excessive action. This partial action approach balances the need for adequate enzyme replacement to improve motor function with the need to avoid saturation effects and potential adverse reactions from过高 dosing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The treatment with sALP significantly increases BOT-2 strength and running speed scores, decreases CHAQ disability indices, and enhances PODCI scores, leading to sustained improvements in physical abilities and reduced pain over several years, allowing children with HPP to perform daily activities with greater ease and reduced discomfort.
Implementation Method 1
Administration of a soluble alkaline phosphatase (sALP), such as asfotase alfa
Implementation Method 2
tissue-nonspecific alkaline phosphatase (TNALP)
Data Source
AI summary
The disclosure features methods for treating hypophosphatasia (HPP) in a patient (e.g., a child having HPP) exhibiting physical impairments, disability in activities of daily living (ADL), pain, and/or delayed motor development by administering a soluble alkaline phosphatase (sALP) to the patient.